Genotypic Resistance Assays: Can They Replace Standard AST?

Clinical treatment, unfortunately, asks a broader question: will this organism actually grow in the presence of this drug, and at what concentration will growth stop?

That is the functional gap between genotypic and phenotypic antimicrobial susceptibility testing. Molecular resistance detection can shorten the path to an important result, particularly when a small number of well-characterized markers carry strong predictive value. But it does not automatically produce a complete susceptibility profile, a Minimum Inhibitory Concentration (MIC), or a reliable answer for every antimicrobial on the menu.

The molecular assay is not the replacement for standard AST. It is an additional instrument—useful, sometimes urgent, and still bounded by what it was designed to detect.

The functional gap: why phenotypic AST remains the gold standard

Phenotypic antimicrobial susceptibility testing measures the thing clinicians ultimately care about: the organism’s response to an antimicrobial.

In a conventional workflow, the laboratory grows the bacterium and exposes it to antibiotics using methods such as disk diffusion or broth dilution. The readout reflects bacterial behavior under the test conditions. Growth is inhibited, or it is not. Depending on the method, the laboratory can classify the isolate as susceptible, intermediate, or resistant and may determine an MIC—the lowest concentration of an antimicrobial that prevents visible growth.

This is not elegant in the software sense. It is not instant. It involves culture, preparation, incubation, controls, interpretation, and sometimes a second look by an experienced technologist. Yet the method has a major advantage over a gene list: it evaluates phenotype.

That distinction matters because antimicrobial resistance is not a single, tidy mechanism. A bacterium may resist a drug through a known gene, an uncharacterized mutation, altered expression, reduced permeability, efflux, enzymatic activity, target modification, or a combination of mechanisms. The organism does not care whether the mechanism fits neatly into a commercial panel.

A molecular assay does.

A genotypic test can only report the resistance determinants included in its design. If the assay targets mecA, vanA, or vanB, it may provide highly actionable information in the right clinical and microbiological context. These markers are among the comparatively well-established examples where the relationship between genotype and phenotype is predictable. But they are exceptions to a much messier rule.

Phenotypic AST remains the clinical reference point because it asks the final functional question rather than inferring the answer from selected genetic evidence.

A resistance gene is evidence of a mechanism. Phenotypic AST is evidence of what the organism actually does.

The difference is not academic. It changes how results are interpreted, how therapy is selected, and whether the laboratory can safely report a complete susceptibility profile.

Genotypic AST is rapid—but usually qualitative

The attraction of rapid molecular antimicrobial resistance detection is obvious. PCR-based assays can identify resistance markers directly from clinical material or from a culture, often before a conventional susceptibility workflow is complete. In a patient with suspected bloodstream infection, that time advantage can influence escalation, de-escalation, isolation decisions, or the urgency of infectious disease review.

But rapid detection is not the same as quantitative susceptibility testing.

Most molecular resistance assays provide a qualitative output:

• a target gene or mutation is detected;
• the target is not detected;
• the result is invalid, indeterminate, or technically uninterpretable.

What they generally do not provide is an MIC. That matters because antimicrobial dosing and treatment decisions may depend not only on whether resistance is present, but on the degree of reduced susceptibility and the relationship between the organism’s MIC, the drug exposure, and the relevant clinical breakpoint.

A gene detection result does not normally tell the laboratory whether the MIC is just above a breakpoint or dramatically beyond it. It does not necessarily indicate whether the resistance determinant is expressed. It may not capture the contribution of several mechanisms operating at once.

Phenotypic methods have their own friction. Manual disk diffusion can involve multiple paper disks on a single plate—up to 12 in standard formats—but the process still depends on organism identification, inoculum preparation, incubation, measurement, and interpretation. Broth microdilution can produce MIC values, but it also requires validated conditions and quality control. Automated systems improve workflow integration, yet they do not eliminate the need to understand the biological and regulatory assumptions behind the result.

The choice is therefore not speed versus accuracy in the abstract. It is a question of which information arrives first and what information is still missing.

The practical laboratory question is not whether one platform is fashionable. It is whether the molecular result changes management before phenotypic AST is available—and whether that change remains defensible when the full profile arrives.

The MIC problem is not a minor detail

The genotypic vs phenotypic antimicrobial susceptibility testing debate often becomes distorted by the word “rapid.” Fast is valuable. But speed does not compensate for missing dimensions of the result.

An MIC is not a perfect biological truth. It is a measured value produced under defined laboratory conditions. Still, it gives clinicians and microbiologists more than a binary signal. It helps establish how close the organism is to a clinical breakpoint and can be important when the therapeutic window is narrow, the infection is severe, or the organism has reduced susceptibility without a simple resistance marker.

Molecular testing usually does not provide that quantitative layer. Even when a gene is strongly associated with resistance, the assay does not automatically translate its presence into a reliable MIC across every organism, drug, and genetic background.

The difficulty becomes especially obvious with beta-lactam resistance. There are hundreds of beta-lactamase variants and other genetic mutations associated with resistance behavior. Their effects can differ by substrate, expression level, bacterial species, porin background, and the presence of additional mechanisms. A panel that identifies one marker may be clinically useful while still leaving the laboratory unable to infer the full phenotype.

This is where vendor language tends to get ahead of workflow reality. A panel may be marketed as detecting resistance, but “resistance detection” can mean several different things:

1. A well-validated marker predicts a defined phenotype.

This is the strongest use case. The marker has a consistent association with resistance in the relevant organism and specimen context.

2. A marker is associated with resistance but has variable expression or effect.

The result may be informative, but it should not be treated as a complete susceptibility profile.

3. The assay detects a genetic feature of uncertain clinical significance.

This can add information for surveillance or investigation without being immediately actionable for treatment.

4. The assay detects a marker but not the organism responsible for disease.

The molecular result may be technically correct and clinically unhelpful.

5. The target is absent, but another resistance mechanism is present.

A negative result can be mistaken for susceptibility when it only means that the specific target was not detected.

That last category is particularly important. The absence of a targeted resistance gene does not necessarily predict susceptibility to the corresponding antimicrobial. Negative molecular evidence is not the same thing as a phenotypic susceptible result.

Discordance is where the workflow gets tested

Genotypic AST discordance with MIC is not an edge case to be hidden in a validation appendix. It is a predictable consequence of comparing two different biological measurements.

The molecular method asks whether selected nucleic acid targets are present. Phenotypic AST asks how the viable organism behaves under antimicrobial exposure. When the results disagree, neither test should be treated as automatically infallible. The discrepancy needs context, investigation, and an explicit reporting policy.

Several patterns can produce discordance:

Gene detected, phenotype apparently susceptible

A resistance marker may be present but not expressed at a level that produces the expected phenotype under the test conditions. The detected DNA may also come from an organism that is not the primary pathogen, especially in specimens containing mixed flora.

The molecular result can therefore be analytically positive without being clinically decisive.

Gene not detected, phenotype resistant

The assay may not include the relevant gene or mutation. The organism may carry a variant outside the assay’s target region, use a different resistance mechanism, or express resistance through a combination of mechanisms that the panel was never designed to capture.

This is one reason negative molecular results require restraint. The report should not imply that the organism is susceptible simply because a selected marker was absent.

Molecular detection from a mixed specimen

Direct-from-specimen assays are particularly vulnerable to the question of ownership: which organism carries the detected target? If the sample contains multiple organisms, the target may not belong to the pathogen driving the infection. Identification and resistance detection can become decoupled.

The software interface may present a clean result. The specimen biology is less cooperative.

Phenotypic result affected by method conditions

Phenotypic AST is the functional reference, but it is not immune to technical problems. Inoculum, incubation, media, reading conditions, contamination, mixed cultures, and borderline growth can all affect interpretation. A discordant result should prompt review of both methods, not a reflexive declaration that molecular testing has uncovered a failure of culture.

A robust laboratory workflow treats discordance as a defined operational event. It does not leave the issue to whichever result appears first on the screen.

Useful safeguards include:

• linking the molecular result to organism identification rather than reporting a resistance marker in isolation;
• defining which markers are considered strongly predictive in each organism-drug context;
• reflexing selected discordant cases to repeat phenotypic testing or an alternative method;
• documenting how negative molecular results are worded;
• monitoring discordance rates by specimen type, organism, resistance target, and platform;
• involving microbiology leadership when the result would trigger a major change in therapy or infection-control response.

This is workflow integration, not a technical afterthought. A molecular panel that creates more ambiguous calls than actionable ones has not solved the laboratory’s bottleneck. It has moved the bottleneck to interpretation.

The problem of non-viable DNA and normal flora

PCR detects nucleic acid. It does not prove that the microorganism is alive, causing disease, or responsible for the resistance phenotype seen in a culture.

That distinction is central when assays are applied directly to clinical specimens. DNA from non-viable organisms can remain detectable after antimicrobial exposure or after the organism has otherwise lost clinical relevance. A resistance target may also be carried by normal flora or by a colonizing organism that is not causing the infection.

This creates a specific form of molecular overdiagnosis: the test identifies a real target, but the result does not answer the clinical question the care team thinks it answered.

Consider the difference between these statements:

• a resistance gene was detected in the specimen;
• the causative pathogen carries the resistance gene;
• the pathogen is phenotypically resistant to the selected antimicrobial;
• the patient’s infection requires a different treatment.

Those are four different claims. A single PCR result may support the first. It does not automatically establish the other three.

The risk is not limited to individual treatment decisions. Overcalling resistance can lead to broader-spectrum therapy, unnecessary escalation, longer exposure to toxic agents, and additional stewardship work. In infection-control settings, a molecular signal may influence isolation or screening decisions even when the organism is not viable. That may be appropriate in a defined surveillance context, but it should not be confused with evidence of active infection.

Clinical microbiology laboratories need specimen-specific interpretation. A molecular resistance panel used on a positive blood culture with a defined organism is a different proposition from one applied directly to a polymicrobial wound, respiratory sample, or other specimen where colonization and mixed flora are common.

The assay cannot solve a pre-analytical ambiguity that the specimen itself contains.

The fastest resistance result is still the wrong result if the detected gene belongs to the wrong organism—or to no viable organism at all.

Where molecular resistance markers earn their place

None of this makes genotypic testing a decorative accessory. Used within a defined algorithm, it can deliver information at a point when phenotypic AST is not yet available.

The strongest deployment model is complementary:

1. Use molecular testing for high-value, well-characterized targets.

Markers with a strong and reproducible relationship to phenotype are more suitable for early clinical decisions than broad collections of weakly predictive genes.

2. Use the result to accelerate a decision, not to pretend the full profile already exists.

Molecular detection can support early therapy adjustment while culture-based identification and phenotypic AST continue.

3. Keep phenotypic testing in the workflow when a full susceptibility profile is required.

The need for MIC values, detection of unexpected mechanisms, or testing against drugs not represented by the molecular panel does not disappear.

4. Build the report around interpretation, not target inventory.

A long list of detected genes is not automatically useful. The report should make clear what the result supports, what it does not establish, and whether additional AST is required.

5. Audit clinical impact after deployment.

Laboratory managers should monitor time to actionable result, therapy changes, discordant findings, invalid rates, unnecessary escalations, and the number of molecular results that do not map cleanly to an identified pathogen.

The deployment question is also financial and operational. A rapid assay may reduce time to selected information while adding instrument maintenance, consumables, training, middleware work, verification requirements, and interpretive calls. If the laboratory still performs phenotypic AST for most specimens—and often should—the molecular platform adds a layer to the workflow rather than replacing one.

That may be entirely justified. But the business case should describe the actual layer being added.

A practical division of labor

For many laboratories, the most defensible architecture looks something like this:

• molecular testing provides an early answer for selected resistance markers;
• culture establishes viable organism recovery and supports identification;
• phenotypic AST evaluates functional response and supplies susceptibility categories or MICs;
• microbiologists reconcile discordant findings;
• clinicians receive a result with explicit scope and limitations.

This model is less dramatic than the promise of replacing culture-based AST. It is also more likely to survive contact with mixed specimens, unfamiliar mechanisms, and the first result that does not behave as the brochure predicted.

What a laboratory should stress-test before implementation

The assay’s technical performance is only one part of readiness. Before deployment, a laboratory needs to understand what will happen on ordinary days, not just in a clean validation set.

Key questions include:

• Which organisms and specimen types are validated for direct testing?
• Which resistance genes or mutations are included, and which clinically important mechanisms are excluded?
• Does the platform identify the organism and the resistance marker in the same result, or can those outputs become disconnected?
• How are mixed cultures, polymicrobial specimens, and low-level targets handled?
• What is the reporting language for a detected marker when phenotype is not yet available?
• What does a negative result explicitly avoid claiming?
• Which discordant combinations trigger repeat testing, sequencing, or additional phenotypic work?
• Can the laboratory connect molecular results to the eventual MIC and susceptibility category for retrospective review?
• What happens when the molecular result arrives outside normal microbiology review hours?
• Are clinicians likely to interpret a detected marker as a complete resistance profile?

That final question is not a user-education footnote. It is a safety issue.

A laboratory can have a technically valid assay and still create clinical confusion if the interface presents a binary “resistant” label without organism, target, scope, and follow-up context. Clinical software has a habit of turning nuanced laboratory evidence into a green or red icon. The icon is not the interpretation.

The verdict: complement, not replacement

Genotypic resistance assays are ready for clinical use when their role is narrow, explicit, and integrated with the rest of the microbiology workflow. They can provide rapid molecular antimicrobial resistance detection, highlight selected high-risk mechanisms, and support earlier decisions in situations where waiting for phenotypic AST has a real clinical cost.

They are not ready to replace standard phenotypic susceptibility testing across routine practice.

The reason is functional, not nostalgic. Molecular assays detect known genetic signals. Phenotypic AST measures the organism’s actual response and can provide quantitative MIC information that most genotypic methods do not. Gene presence can mislead. Gene absence can reassure falsely. DNA can come from non-viable organisms or normal flora. Resistance mechanisms remain more diverse than the target menu on any commercial panel.

So the binary answer is clear: genotypic resistance assays can supplement phenotypic AST, but they cannot currently replace it as the general clinical standard.

Deploy the molecular test where it shortens the path to a defensible decision. Keep phenotypic AST where the question is the organism’s complete, functional susceptibility profile. That is not a failure of molecular diagnostics. It is the boundary between detecting a mechanism and measuring resistance.